Synthesis and spectroscopic characterization of double salts ionic liquids of quinidine
Polymorphism, the interconversion of solid state material between different crystalline forms, can reduce the effectiveness of solid state drugs. Injury caused by medications is the leading cause of death in the United States. Drug induced liver injury is any form of liver injury caused by medication. A common solution to these problems is the conversion of the solid state drugs into their liquid forms via an ionic liquid (IL) formation; an active pharmaceutical ingredient (API) and an FDA approved compound or two APIs can be combined in their cationic or anionic form into a single ionic compound leading to the formation of new dual active APIs in liquid form (API-IL, ILs that melt below 37 ℃) that will retain the pharmaceutical properties of the original APIs. Combining three or more drugs into one single ionic compound, namely a double salt ionic liquid (DSIL), would allow one to add additional properties to the final liquid drug. Our research focuses on applying the DSIL strategy to pharmaceuticals that cause liver injury (quinidine) by combining them with drugs that offer liver protection properties (N-acetyl-L-cysteine, NALC), and compounds that will increase their permeability (sodium docusate, NaDoc) adding a new delivery mechanism to the drug. This presentation shows the synthesis and spectroscopic characterization of new DSILs formed by combining quinidine in its cationic form with NALC and NaDoc in their anionic form in different cation to anion molar ratios.